Author at Microdose

Patrick McConnell

Patrick McConnell is a freelance writer who first became fascinated with psychedelics during an anti-drug presentation in high school. Previously he has worked as a treeplanter, orchardist, and cannabis farmer. After drinking ayahuasca in 2020, he quit his job, sold everything he owned, and now resides in the Peruvian Andes with his wife and cat.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Culture

2 Mar 2023

Building Models for Psychedelic Integration

Psychedelic integration....

By Patrick McConnell

Health & Wellness

16 Feb 2023

Adverse Ayahuasca Experiences Lead to Growth

Ayahuasca has a reputation for being a difficult ride....

By Patrick McConnell

Science

24 Jan 2023

The Microbiome and Psychedelics: It’s Not All in Your Head

The Microbiome and Psychedelics....

By Patrick McConnell

Culture

2 Dec 2022

A Deeper Look at Psychedelics Anonymous

Psychedelics Anonymous or “PA,” is a project of NFTs or non-fungible tokens, but also works to educate about psychedelics and make a real impact on addressing mental health....

By Patrick McConnell

Join Our Newsletter for Exclusive Updates, Stories, and More

Science

17 Nov 2022

Predicting Psychedelic Outcomes

Can we better predict psychedelic outcomes? Imagine psychedelic settings curated to the individual, the right therapist, music, and even substance....

By Patrick McConnell

Science

1 Nov 2022

Decoding the Difference Between 5-MeO-DMT and N, N-DMT

While there are similarities between the two compounds, it’s important to understand that N, N-DMT and 5-MeO-DMT have significantly different effects and possible potential....

By Patrick McConnell

Law & Politics

25 Oct 2022

ATMA Journey Centers and Legal Psychedelics in Canada

The CEO of ATMA, David Harder, outlines a different path for psychedelics, one of government acceptance through cooperation with governmental bodies, training professionals, and clinical trials....

By Patrick McConnell

Industry, Science

20 Oct 2022

A Deeper Look at Ketamine and its Potential for Addiction

Ketamine might be the current poster child for psychedelic medicine, but mainstream media has been missing an important reality about ketamine's divergence and potential for addiction....

By Patrick McConnell

Law & Politics

17 Oct 2022

What Do Biden’s Cannabis Pardons Mean for Psychedelics?

The Biden administration's unconditional pardon announced on Oct 6 presents a much wider opportunity, which could also be a breakthrough in the long term for psychedelics....

By Patrick McConnell

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

Latest News

You Might Also Like

11 Aug 2026

Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High

Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the antidepressant benefits people associate with psychedelics without the trip? On...

By Madison Roberts

28 Jul 2026

FDA’s New Psychedelic Guidance Signals a Maturing Industry. Now Comes the Hard Part.

For years, the psychedelic medicine industry has operated in largely uncharted regulatory territory. Companies developing psilocybin, LSD, MDMA, and next-generation psychedelic-inspired compounds have often found themselves navigating a clinical landscape...

By Madison Roberts

13 Jul 2026

The Psychedelic Sector Has Grown Up. Wall Street Just Hasn’t Fully Realized It Yet

The sector experienced an early wave of enthusiasm fueled by bold promises, lofty valuations, and the belief that psychedelic medicine would quickly transform mental healthcare. Reality, however, proved more complicated....

By Madison Roberts

28 May 2026

Medical Psilocybin Act

New York lawmakers are officially considering the “Medical Psilocybin Act,” legislation that would create legal access to psilocybin therapy for conditions like PTSD, treatment-resistant depression, substance use disorders, end-of-life distress,...

By Madison Roberts

5 May 2026

PTSD, Policy Shifts, and the Rise of Neuroplastogens: What Enveric’s Latest Data Signals for the Field

By Madison Roberts

21 Apr 2026

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

President Donald Trump’s April 2026 executive order on accelerating treatments for serious mental illness does something the psychedelic industry has been waiting for, and quietly fearing. It removes ambiguity. For...

By Madison Roberts

Patrick McConnell is a freelance writer who first became fascinated with psychedelics during an anti-drug presentation in high school. Previously he has worked as a treeplanter, orchardist, and cannabis farmer. After drinking ayahuasca in 2020, he quit his job, sold everything he owned, and now resides in the Peruvian Andes with his wife and cat.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

WordPress Ads